Breaking News
FONT-SIZE Plus   Neg
Share SHARE

CVS Caremark Reaches $11 Mln Settlement With US DoJ For Drug Law Violations

The U.S. Department of Justice announced Wednesday that drug store chain CVS Caremark Corp. (CVS: Quote) has agreed to pay a fine of $11 million to settle civil penalty claims involving violations of Controlled Substances Act. This is one of the largest settlements ever paid for record-keeping violations by a retail pharmacy chain related to controlled pharmaceuticals.

The settlement was announced by U.S. Attorney for the Western District of Oklahoma Sanford Coats. CVS acknowledged that its stores must comply with the record-keeping requirements, but did not admit liability.

"The abuse of prescription drugs is a well-documented epidemic inflicting devastating, long-term, effects on individuals, families, and entire communities. To combat this problem, it is essential that those who dispense controlled substances comply with DEA's record-keeping requirements," Coats said in a statement.

The settlement resolves allegations that the company's Oklahoma pharmacies violated the Controlled Substances Act by failing to keep proper records of pharmacy drug sales.

The Act calls for pharmacies to document each transaction that involves controlled substances or powerful prescription drugs, along with the U.S. Drug Enforcement Administration or DEA, registration numbers of the doctors prescribing those drugs.

Each DEA registrant, including pharmacies, is required to maintain complete and accurate records of each substance manufactured, received, sold, delivered, dispensed or otherwise disposed of by the registrant for two years.

The process ensures that dispensers of prescription drugs remain accountable and these drugs are not illegally diverted to addicts and street dealers. The DoJ noted that abuse of prescription drugs is one of the most critical issues it faces currently.

The Woonsocket, Rhode Island-based company was charged of using dummy registration numbers for prescriptions, and filling prescriptions written by doctors whose DEA registrations were no longer valid. These violations occurred between October 2005 to October 2011 at two CVS pharmacies in Oklahoma.

The Acting Special Agent in Charge of the DEA Dallas Field Division, Daniel Salter, said, "This settlement reinforces the responsibilities of all pharmacies to prevent the diversion of dangerous drugs. This case highlights DEA's steadfast resolve to combat the growing prescription drug abuse problem in this country by ensuring that all DEA registrants, including nationwide pharmacy chains, are in compliance with the law. This is vital to protect public health and keep our communities safe."

CVS closed Wednesday's regular trading session at $54.13, down $1.11 or 2.01% on a volume of 6.75 million shares.

Register
To receive FREE breaking news email alerts for CVS Caremark Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks moved notably higher over the course of the trading day on Friday after initially showing a lack of direction. The gains on the day extended the recent upward trend by the markets, with the tech-heavy Nasdaq reaching its best closing level in almost a month. Looking to capitalize on news of an Ebola diagnosis in New York City, Republican Senate candidate Scott Brown issued a statement Friday criticizing his Democratic opponent Sen. Jeanne Shaheen, D-N.H., for "waffling" on a travel ban. In another troubling sign for Democrats, the results of a Gallup poll released on Friday show that Tea Party Republicans are much more motivated to vote in the upcoming midterm elections than other Americans. The poll found that 73 percent of Tea Party Republicans are "extremely" or "very" motivated to vote in this year's elections.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.